Because PRMT5/MEP50 inhibition significantly induced the suppression of cell proliferation and client proteins in leukaemic cells from ATL patients, we herein propose that interference with cytoplasmic PRMT5/MEP50 is a feasible and effective strategy for promoting cancer vulnerability in NDRG2low ATL and various cancer cells. The gene discussed is PRMT5; the disease is cancer.